Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-4000 Consolidation in KRAS-Mutated NSCLC
NCT00655161Phase 2Completed
- Sponsor
- GlobeImmune
- Start
- Apr 2008
- Primary completion
- Nov 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GI-4000 in non-small cell lung cancer (NSCLC), sponsored by GlobeImmune. Started Apr 2008; status: completed.
02
Drugs
GI-4000
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00655161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00655161.